Company intelligence / Profile preview

Sanol GmbH

Ownership: Private
Development stage: Commercial

Overview

Sanol GmbH has developed ferrous sulfate glycine mixed salt enteric-coated capsules for the treatment of iron deficiency anemia. In two Phase 3 clinical trials, this product demonstrated non-inferiority to polysaccharide iron complex capsules after 12 weeks of treatment in patients with iron deficiency anemia.

Therapeutic areas: Hematology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

3 assets

Digiblue

Commercial

Indications: Digital eye strain

2 more assets in the full pipeline.

Partnerships

Schwarz Pharma Produktions GmbH

Beyond the preview

Go deeper on Sanol GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanol GmbH.